Prevalence

IN A RECENT STUDY OF OVER 1,000 PEOPLE WITH DIFFICULT-TO-CONTROL TYPE 2 DIABETES (T2D), 24% WERE DIAGNOSED WITH ENDOGENOUS HYPERCORTISOLISM1*

CATALYST—the largest US prospective clinical trial ever conducted to investigate the prevalence of endogenous hypercortisolism—revealed that nearly 1 in 4 people with difficult-to-control T2D had endogenous hypercortisolism.2

Difficult-to-control T2D was defined as people having an HbA1c of ≥7.5% and ≤11.5% and taking2:

  • 3 or more T2D medications OR

  • Insulin and other T2D medication(s) OR

  • 2 or more T2D medications AND

    • The presence of ≥1 microvascular or macrovascular complications AND/OR

    • 2 or more hypertension medications

Learn more about hyperglycemia due to hypercortisolism.

STUDY DETAILS

Nearly 1 in 4 (24%) of people with difficult-to-control T2D had endogenous hypercortisolism1

Endogenous hypercortisolism was defined as2:

  • 1-mg DST >1.8 μg/dL

  • Confirmed dexamethasone level ≥140 ng/dL

24 percent (252/1057).

More than 1 in 3 people (37%) with difficult-to-control T2D who were taking ≥3 hypertension medications had endogenous hypercortisolism1*

PREVALENCE OF ENDOGENOUS HYPERCORTISOLISM IN PEOPLE WITH DIFFICULT-TO-CONTROL T2D WHO WERE TAKING ≥3 HYPERTENSION MEDICATIONS

36.6 percent (86/235).

The Risk Of Hypercortisolism Doubled In People Taking Medications For T2d And Hypertension1*

~2x INCREASED
RISK

People taking hypertension medications (OR 2.241, 95% CI 1.443, 3.481)

People taking ≥2 T2D medications AND having hypertension requiring ≥2 hypertension medications (OR 1.934, 95% CI 1.452, 2.577)

CATALYST was a phase 4, two-part, multicenter trial. Part one (screening phase) primary endpoint was to determine the prevalence of hypercortisolism in people with difficult-to-control type 2 diabetes (N=1057). Participants were screened with a 1-mg DST. Hypercortisolism defined as cortisol >1.8 μg/dL with dexamethasone ≥140 ng/dL.1,2

Hypercortisolism can lead to worsening T2D and hypertension3

VIEW DATA

The 1-mg dexamethasone suppression test detects all etiologies of hypercortisolism2

VIEW SCREENING

Contact a rep and stay informed about recent data

SIGN UP

References

1. Buse JB, Kahn SE, Aroda VR, et al. Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes: updated results from CATALYST part 1 [symposium]. Presented by Fonseca, V. at the 22nd World Congress Insulin Resistance Diabetes & Cardiovascular Disease; December 12-14, 2024; Los Angeles, CA. 2. DeFronzo RA, Auchus RJ, Bancos I, et al. BMJ Open. 2024;14(7):e081121. doi:10.1136/bmjopen-2023-081121 3. Elhassan YS, Alahdab F, Prete A, et al. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630 4. Nieman LK, Biller BMK, Findling JW, et al. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818 5. Ciftel S, Mercantepe F. Cureus. 2023;15(11):e48383. doi:10.7759/cureus.48383 6. Giovanelli L, Aresta C, Favero V. J Endocrinol Invest. 2021;44(8):1581-1596. doi:10.1007/s40618-020-01484-2 7. Aresta C, Soranna D, Giovanelli L, et al. Endocr Pract. 2021;27(12):1216-1224. doi:10.1016/j.eprac.2021.07.014